At DBMR, we are continuously striving to become one of the most trusted companies in the world, uniquely positioned to provide emerging healthcare technology market intelligence solutions and market research reports for- Medical Devices, Healthcare IT & Services, Life Sciences & Biotech, and Emerging Healthcare Technologies, covering the entire industry spectrum.

Benign prostatic hyperplasia is also called as BPH which is a condition in men where the prostate gland is enlarged and is not cancerous. Benign prostatic hyperplasia is also known as benign prostatic obstruction or benign prostatic hypertrophy. The prostate usually goes through 2 main growth stages as a man ages. The first stage happens early in puberty, when prostate doubles in size, whereas the second phase of growth occurs around the age of 25 and continues through most of a man’s life. BPH often happens with the second stage of growth.

North America benign prostatic hyperplasia devices market is expected to reach at a CAGR of 11.9% in the forecast period of 2019 to 2026.

North America benign prostatic hyperplasia devices market is segmented based on procedure type and end user.

On the basis of procedure type, the market is segmented into transurethral resection of the prostate (TURP), prostatic urethral lift, prostatectomy, laser surgery, transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA), prostatic stenting/implants and others. Laser surgery is sub-segmented into holmium lasers, green light laser/PVP and thulium laser based devices. The others segment is sub-segmented into water-induced thermotherapy, high-intensity frequency ultrasound (HIFU), prostatic artery embolization (PAE) and others. Prostatectomy segment is growing at the highest CAGR of 12.7% in the forecast period of 2019 to 2026.

In October 2015, Lumenis launched pulse laser systems which can be used for the prostate and stones treatment. The Pulse 50H laser and Pulse 100H systems is designed for the treatment of benign prostatic hyperplasia (BPH) and stones. The additions of pulse products show a key development to current urological solutions. This addition will help in increasing the company’s product line.

On the basis of end user, the market is segmented into hospitals and clinics and ambulatory surgical centers. Hospitals and clinics are growing at the highest CAGR of 12.2% in the forecast period of 2019 to 2026.

In February 2019, Teleflex Incorporated’s subsidiary Neotract, Inc (U.S.) expanded its UroLift business. Humana which is a one of the nation’s largest private health insurers is now providing insurance coverage for the UroLift system. This will help the company in grasping more customers.

In January 2019, Boston Scientific Corporation has launched Rezūm water vapor therapy and the randomized clinical trial results shows that it offers long-lasting results in minimally invasive treatment for benign prostatic hyperplasia (BPH). This product launch will increase the company’s product line.

In March 2017, Biolitec has launched XCAVATOR laser fiber which can be used in the benign prostatic hyperplasia (BPH) treatment. The laser fiber can remove tissue on the prostate at a rate of 3 to 4 grams per minute. This new technological advanced product will offer the urologist an attractive option for their surgery and this will help to increase the company’s product line.

In January 2016, Medifocus Inc. announced the engagement of the Tanaka Kapec Design Group, Inc. as a lead designer of the next generation Prolieve Thermodilatation System. This combinational therapy helped in offering both immediate and the long term relief in the BPH related symptoms.

In October 2015, Lumenis launched pulse laser systems which can be used for the prostate and stones treatment. The Pulse 50H laser and Pulse 100H systems is designed for the treatment of benign prostatic hyperplasia (BPH) and stones. The additions of pulse products show a key development to current urological solutions. This addition will help to increase the company’s product line.

In September 2014, Lisa Laser USA has launched RevoLix 200watt for the BPH treatment. It uses the wavelength of 2013 nm, which targets the water in the tissue, providing superior vaporization, cutting and hemostasis of the prostate. The company will be benefitted from the launch as the product launch will increase the company’s product portfolio.

In 2011, Urologix signed an exclusive worldwide license for Prostiva RF Therapy System which is used for BPH treatment from Medtronic, Inc. This helped in expanding the product portfolio of the company.

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service